Specifically, 91.1% of vitiligo patients achieved seroconversion after the first dose, with 100% after the second dose, indicating strong vaccine efficacy.

Importantly, only three patients required hospitalization due to COVID-19, suggesting severe outcomes were rare among those with DIMIDs.

Despite some patients reporting increased disease activity, the study found no alarming signs regarding severe COVID-19 risk in patients with DIMIDs, underscoring the importance of vaccination.

Immunosuppressive therapy did not correlate with a higher risk of developing COVID-19 or increased disease activity, indicating that patients can safely continue their treatment.

The study also identified vaccination, a healthy diet, and the presence of atopic conditions as protective factors against COVID-19.

Finally, the study emphasizes the need for further research to understand the long-term effects of COVID-19 and vaccination on DIMIDs.

The COVID-19 pandemic significantly affected patients with dermatological immune-mediated inflammatory diseases (DIMIDs), such as atopic dermatitis, psoriasis, and vitiligo, primarily due to fears of morbidity and mortality, as well as vaccine hesitancy.

Among these patients, those with vitiligo exhibited the highest risk of developing COVID-19, with an incidence rate of 51.1%, compared to 42.0% for atopic dermatitis and 34.3% for psoriasis.

During the pandemic, individuals with atopic dermatitis reported lower life satisfaction and health ratings, highlighting the psychological impact of the crisis.

A recent study led by Nicoline F. van Buchem-Post from Amsterdam University Medical Centers, published in The Journal of Dermatology, evaluated the effects of COVID-19 and vaccination on patients with DIMIDs.

The study involved 424 patients with an average age of 44 years, who were monitored for COVID-19 development, vaccination responses, and changes in disease activity through electronic forms and patient-reported questionnaires.

Findings revealed that patients on immunosuppressants had comparable seroconversion rates to controls, with high rates of effective seroconversion post-vaccination: 100% for vitiligo, 97.9% for psoriasis, and 96.5% for atopic dermatitis after the second vaccination.